May 9, 2024, Hong Kong King-Friend Industrial Company Limited. (hereinafter referred to as "HKF"), a subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "NKF"), received the approval letter from the US Food and Drug Administration (FDA) for Eptifibatide injection.

Eptifibatide injection is an anticoagulant drug used in the treatment of acute coronary syndrome. It can reversibly inhibit platelet aggregation and treat patients with unstable angina pectoris and non-ST-segment elevation myocardial infarction. 

NKF holds more than 80 approval letters from USFDA. The approval of Eptifibatide injection increase the pipeline products, reflecting the mission to continue to provide high-quality medicines to patients with critical diseases worldwide.